Literature DB >> 2254893

Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis.

I Lundberg1, E Hedfors.   

Abstract

To analyze whether corticosteroids in low doses during limited time periods could be safely used in the treatment of patients with polymyalgia rheumatica (PMR) or temporal arteritis (TA) the records of 91 patients diagnosed between 1980 and 1987 were reviewed. The mean initial prednisolone dose was in patients with PMR 18 mg/day and the mean duration of treatment was 17 months. In patients with TA the mean initial dose was 31 mg/day and the mean duration of treatment 16 months, and in all the corticosteroid treatment was terminated within 24 months. Patients with coexisting TA and PMR demanded longer treatment compared to patients with either TA or PMR and thus 18/91 patients were treated for more than 2 years. No visual or neurological complications occurred after treatment with corticosteroids had been initiated. Our study indicates that most patients with PMR or TA can be treated safely with an initial prednisolone dose of 10 mg given twice daily. With few exceptions corticosteroid treatment can be terminated within 24 months.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2254893

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  11 in total

Review 1.  The treatment of giant cell arteritis.

Authors:  J Alexander Fraser; Cornelia M Weyand; Nancy J Newman; Valérie Biousse
Journal:  Rev Neurol Dis       Date:  2008

Review 2.  Giant cell arteritis: Current treatment and management.

Authors:  Cristina Ponte; Ana Filipa Rodrigues; Lorraine O'Neill; Raashid Ahmed Luqmani
Journal:  World J Clin Cases       Date:  2015-06-16       Impact factor: 1.337

3.  Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.

Authors:  Haner Direskeneli; Sibel Z Aydin; Tanaz A Kermani; Eric L Matteson; Maarten Boers; Karen Herlyn; Raashid A Luqmani; Tuhina Neogi; Philip Seo; Ravi Suppiah; Gunnar Tomasson; Peter A Merkel
Journal:  J Rheumatol       Date:  2011-07       Impact factor: 4.666

Review 4.  Clinical diagnosis and management of large vessel vasculitis: giant cell arteritis.

Authors:  Soumya Chatterjee; Scott D Flamm; Carmela D Tan; E Rene Rodriguez
Journal:  Curr Cardiol Rep       Date:  2014-07       Impact factor: 2.931

Review 5.  Clinical features of polymyalgia rheumatica and giant cell arteritis.

Authors:  Carlo Salvarani; Nicolò Pipitone; Annibale Versari; Gene G Hunder
Journal:  Nat Rev Rheumatol       Date:  2012-07-24       Impact factor: 20.543

6.  Healthcare Use and Direct Cost of Giant Cell Arteritis: A Population-based Study.

Authors:  Matthew J Koster; Sara J Achenbach; Cynthia S Crowson; Hilal Maradit-Kremers; Eric L Matteson; Kenneth J Warrington
Journal:  J Rheumatol       Date:  2017-05-01       Impact factor: 4.666

7.  Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study.

Authors:  Cristian Labarca; Matthew J Koster; Cynthia S Crowson; Ashima Makol; Steven R Ytterberg; Eric L Matteson; Kenneth J Warrington
Journal:  Rheumatology (Oxford)       Date:  2015-09-18       Impact factor: 7.580

8.  The effect of a nurse-led prednisolone tapering regimen in polymyalgia rheumatica: a retrospective cohort study.

Authors:  Christoffer Mørk; Mette Y Dam; Mikkel G Callsen; Kresten K Keller
Journal:  Rheumatol Int       Date:  2020-07-21       Impact factor: 2.631

9.  Long term treatment of polymyalgia rheumatica with deflazacort.

Authors:  M A Cimmino; G Moggiana; C Montecucco; R Caporali; S Accardo
Journal:  Ann Rheum Dis       Date:  1994-05       Impact factor: 19.103

Review 10.  Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus.

Authors:  Christian Dejaco; Christina Duftner; Marco A Cimmino; Bhaskar Dasgupta; Carlo Salvarani; Cynthia S Crowson; Hilal Maradit-Kremers; Andrew Hutchings; Eric L Matteson; Michael Schirmer
Journal:  Ann Rheum Dis       Date:  2010-11-19       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.